Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Jul 22;217:104394. doi: 10.1016/j.chemolab.2021.104394

Identification of Food Compounds as inhibitors of SARS-CoV-2 main protease using molecular docking and molecular dynamics simulations

Vijay H Masand a,, Md Fulbabu Sk b, Parimal Kar b, Vesna Rastija c, Magdi EA Zaki d
PMCID: PMC8295492  PMID: 34312571

Abstract

SARS-CoV-2 has rapidly emerged as a global pandemic with high infection rate. At present, there is no drug available for this deadly disease. Recently, Mpro (Main Protease) enzyme has been identified as essential proteins for the survival of this virus. In the present work, Lipinski's rules and molecular docking have been performed to identify plausible inhibitors of Mpro using food compounds. For virtual screening, a database of food compounds was downloaded and then filtered using Lipinski's rule of five. Then, molecular docking was accomplished to identify hits using Mpro protein as the target enzyme. This led to identification of a Spermidine derivative as a hit. In the next step, Spermidine derivatives were collected from PubMed and screened for their binding with Mpro protein. In addition, molecular dynamic simulations (200 ns) were executed to get additional information. Some of the compounds are found to have strong affinity for Mpro, therefore these hits could be used to develop a therapeutic agent for SARS-CoV-2.

Keywords: SARS-CoV-2, COVID-19, Food compounds, Virtual screening, Spermidine, Mpro, MD Simulation, Free energy

Graphical abstract

Image 1

1. Introduction

COVID-19, a deadly disease with a high infection rate, is caused by the novel corona virus SARS-CoV-2. It was first reported from Wuhan (China) and then rapidly reached many countries. The virus spreads through human to human contact. Unfortunately, it has survived in different climatic conditions. The high infection rate as well as mortality rate of the disease is reflected from the data released by World Health Organization (https://covid19.who.int/). The emergence of this disease has led to serious socio-economic and health issues for human race [[1], [2], [3], [4], [5]]. Eventhough, vaccines from Moderna, Pfizer, etc. have gained emergency use but they have their own limitations as well as the emergence of new variants of SARS-CoV-2 is a concern [[6], [7], [8], [9]]. But, a safe and effective drug for this highly contagious and fatal disease is need of the hour.

In search of developing such drug it was essential to understand the nature, functioning and bio-chemistry of virus. Researchers quickly found that this virus has more than 70% genome similarity with previously reported corona virus SARS-CoV [1,2,[10], [11], [12], [13]]. The high similarity was further found to exist in essential proteins like main protease, spike S protein, etc. of these two viruses. These proteins are essential for survival and replication of SARS-CoV-2.

Coronavirus (CoV) main protease (Mpro) is a key enzyme that participates in cleavage process of H-CoV polyproteins. Mpro, also known as Nsp5 and 3CLpro, homodimer consists of three domains, domain I (residues 8–101), domain II (residues 102–184) and domain III (residues 201–303), and a long loop (residues 185–200), which connects domains II and III [1,2,[10], [11], [12], [13], [14]]. The active site of this protein is situated in the gap between domains I and II, and the catalytic dyad of Cys145 and His41 is its important feature. Domain I and II have motifs that are representing the chymotrypsin catalytic domain, while domain III participates in the dimerization of protein and active enzyme production [15]. This protein is necessary for the processing of polyproteins and operates at 11 cleavage sites on the large polyprotein 1 ​ab. Fortunately, the cleavage specificity of this protein is different from human proteases; therefore an inhibitor of Mpro could be safe for humans [1,2,5,[10], [11], [12], [13], [14]].

The amino acid sequence and 3D-structures of this protein have been successfully resolved by researcher [15]. Consequently, Mpro has emerged as a valid target for developing a drug for COVID-19 using molecular docking. Molecular docking is a contemporary and rational approach to identify the important structural features that govern the activity profile of a molecule. It can be used for virtual screening to identify novel hits, which could be further optimized to develop a drug candidate.

There is an urgent need to develop a drug to control COVID-19. Unfortunately, transformation of a compound to drug is a time-consuming process due to optimization of ADME (Absorption, Distribution, Metabolism and Excretion) and minimization of toxicity. This could delay development of drug. However, many food compounds have innate ability to have better ADME related properties, or immune stimulatory effects without toxicity [16,17]. Therefore, transforming a food compound or its close derivative is a novel and plausible strategy to speed-up the process of developing a drug for COVID-19. In the present work, we have performed virtual screening of food compounds using Lipinski's rule of five and molecular docking to screen potent inhibitors of this protein from food. In addition, thorough and systematic molecular dynamic simulations (200 ns) were executed to get additional information. The results could served as a tool to develop a safer drug for COVID-19.

2. Experimental section

2.1. Database collection, curation and filtering

In the present work, FooDB (https://foodb.ca/accessed on 11th May 2020) was selected as it comprises a rich collection of food constituents (26,467 compounds). The food database used in the present work comprises a variety of molecules thus covering a broad chemical space. As a part of data curation, all charged molecules, duplicate entries, organometallic compounds, etc. were removed. Then, Lipinski's rule of five was used to filter this database, except that the lower limit for molar mass was set to 150 due to the large size of active site of Mpro (main protease) of SARS-CoV-2 [1,2,5,[10], [11], [12], [13], [14]]. This reduced the pool to a dataset of 7,486 molecules only. In order to narrow down the search, only polyphenols, coumarins and polyamines were selected to filter the reduced dataset. This resulted in a small dataset of 106 compounds only. In the next step, these 106 compounds were docked in the active site of Mpro protein. The molecular docking analysis identified spermidine as a hit with highest binding affinity with the target enzyme. Thereafter, Spermidine derivatives were collected from PubMed database (23 molecules). Molecular docking of these 23 spermidine derivatives was accomplished for Mpro protein. The protocol followed in the present work has been summarized in Fig. 1 .

Fig. 1.

Fig. 1

Flow chart of strategy used in the present work used to identify the hits for essential protein Mpro for SARS-CoV-2.

2.2. Molecular docking

The three-dimensional structure of COVID-19 main protease (COV19-Mpro) in complex with peptidomimetic inhibitor, N3 (pdb: 6lu7), was downloaded from the Protein Data Bank (PDB, https://www.rcsb.org/). The three-dimensional coordinates of water molecules were removed from protein structure using BIOVIA Discovery Studio 4.5 (Dassault Systems, USA). Program iGEMDOCK [18] (BioXGEM, Taiwan) was used for removing co-crystallized ligands and performing molecular docking. Molecular docking was performed on optimized structures (force field: MMFF94) of compounds. Genetic parameters for molecular docking were set on: population size 200; generations 70; number of solution or poses: 3. Active site of Mpro according the bounded synthetic peptidomimetic inhibitor, N3.

After the docking procedure, protein-compound interaction profiles of electrostatic (Elec), hydrogen-bonding (Hbond), and van der Waals (vdW) interactions were generated. Docking poses were ranked by combining the pharmacological interactions and energy-based scoring function (E/kcal mol−1) is: E ​= ​vdW ​+ ​Hbond ​+ ​Elec [18]. Results were viewed and analyzed with BIOVIA Discovery Studio 4.5.

2.3. Molecular dynamics simulations

After docking studies of Mpro and compared the energy-based scoring functions of each food compound, we selected the top three food compound complexes for studying the docked structure's thermodynamics stability. These three best-docked complexes are complex1 (Mpro/7), complex2 (Mpro/17), and complex3 (Mpro/85). We also rename the food compound 7, 17, and 85 to ligand1, ligand2, and ligand3. The molecular dynamics simulations were performed with the AMBER18 [19] package using ff14SB [20] force field for Mpro and updated generalized Amber force field (GAFF2) [21] for food compounds. The protonation states of the charged residues were determined using the Propka 3.1 module [22]. The inhibitors were assigned AM1-BCC [23]charge, which was calculated by utilizing the Antechamber module [24]. The complexes were solvated in a truncated octahedron periodic box with an explicit TIP3P [25] water model and set a buffer distance cut-off at 10 ​Å from any edge to any protein atom. To make the whole system charge-neutral, we add a suitable number of Na+ ions to each system. The protein, complex, and food compounds topology and coordinates were prepared with the tLEaP [26] module of AMBER suite.

Energy minimization of each system was performed by using the very famous steepest descent and conjugate gradient algorithms. All bond lengths involving hydrogen atoms were constrained by the SHAKE algorithm [27]. The particle mesh Ewald summation (PME) [28] approach was employed to treat long-range electrostatic interactions between the Mpro and food compounds. For all cases, the nonbonded Coulomb cut-off was fixed at 10 ​Å. An overall pressure and a temperature equal to 1 ​atm and 300 ​K were used with a time-frequency of 2 fs. The temperature was kept constant inside the box with the Langevin thermostat [29] temperature coupling method and Berendsen Barostat [30] to monitor the system pressure. All the steps of MD run and parameters, we adopted from our previous studies [[31], [32], [33], [34], [35], [36], [37]]. Finally, each system was subjected to 200 ns production MD run with a simulation time step of 2 fs at the NPT ensemble. Overall, we accumulated 20000 conformations for each simulation, and we used 2000 snapshots from the last 100 ns trajectories for binding affinity calculations.

2.4. Trajectory and binding free energy analysis

Trajectory analysis was performed using the AmberTools19 Cpptraj module [38], and all the plots are generated by matplotlib [39]. The binding affinity of ligand1, ligand2, and ligand3 toward SARS-CoV-2 3CL Mpro, were calculated by the molecular mechanics generalized Born surface area (MM-GBSA) method [[40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51]] using MMPBSA.py [52] script based on the MD trajectory. The MM-GBSA free energy ΔGbind was estimated by the following equation:

ΔGbind=ΔHTΔSΔEinternal+ΔGsolvTΔS (1)
ΔEinternal=ΔEcovalent+ΔEelec+ΔEvdW (2)
ΔGsolv=ΔGpol+ΔGnp (3)

Where ΔE internal, ΔG sol, and -TΔS are the change in internal energy at the gas phase, the desolvation free energy, and the conformational entropy upon binding, respectively. ΔE internal is the sum of ΔE convalent (bond, dihedral, and angle energies), ΔE ele (electrostatic), and ΔE vdW (van der Waals) energies. ΔG sol includes ΔG pol (polar contributions or electrostatic solvation energy) and ΔG nonpol (non-polar contributions or non-electrostatic solvation energy). We further calculate the binding free energy contributions at the residual level using by same MM-GBSA decomposition scheme. All the parameters used in this calculation were developed by Onufreiv and Bashford [53]. To investigate protein-food compound interactions pattern of final conformation, LigPlot+ [54] software used.

3. Result and discussion

The data for 106 food ingredients containing polyphenols, coumarins and polyamines are given in Supplementary Files 1 (Table SF1). Scoring function of COVID-19 main protease (COV19-MPro) (pdb: 6lu7) for the best eleven ranked compounds is presented in Table 1 .

Table 1.

Total energies of interactions of the best docked poses of from set of 106 food compounds in complex with COVID-19 main protease (COV19-MPro) (pdb: 6lu7).

Total energy (kcal mol−1) with COV19-MPro
85 (0) −141.27
78 (1) −122.71
68 (0) −120.38
30 (0) −119.89
77 (1) −119.68
4 (1) −118.55
76 (1) −115.57
79 (1) −115.30
3 (0) −114.57
33 (0) −114.46
65 (2) −113.05
Remdesivir (4) −116.05

Compound 85 (N1,N10-dicoumaroylspermidine) achieved the best docking scores among the 106 food ingredients for COV19-MPro (−95.42 kcal mol−1). Compound 85 (N1,N10-dicoumaroylspermidine) derives from a spermidine and a trans-4-coumaric acid and has role as a plant metabolite presents in the Helianthus annuus (sunflower) Vicia faba (faba bean) and Pyrus communis (pear). Considering that spermidine obtained the best docking results for both receptors related to the SARS-CoV-2, further molecular docking was performed on a new set of 24 spermidine derivatives, including compound 85 from the last set.

The data for 24 spermidine derivatives are given in Supplementary Files 2 (Table SF2). The best eleven results of molecular docking performed on COVID-19 main protease are presented in Table 2 .

Table 2.

Total energies of interactions of the best docked poses of spermidine derivatives in complex with COVID-19 main protease (COV19-MPro) (pdb: 6lu7).

Compound (pose) Total energy (kcal mol−1) with COV19-MPro
85 (0) −141.27
7 (2) −130.79
17 (0) −129.08
6 (1) −122.15
18 (0) −121.54
12 (2) −121.45
8 (1) −120.71
13 (0) −116.97
19 (1) −114.85
20 (0) −112.92
22 (0) −102.14
Remdesivir (4) −116.05

From the set of spermidine derivatives, compound 85 again showed the highest affinity for the binding to the COV19-Mpro. Comparing the total energies of interaction for the set of 106 food compounds with energies of spermidine derivatives, three spermidine derivatives have shown better results for COV19-Mpro. Thus, spermidines have proven to be the leading food compounds for the treatment of COVID-19. Observing the mode of interactions of the best ranked compounds, we will try to define structural characteristics important for the inhibition.

Compound 85 is an enamide, a polyphenol, a secondary amino compound and a secondary carboxamide in which each of the primary amino groups has been mono-acylated by formal condensation with trans-coumaric acid. In Table 3 are given the energies of the main interactions with amino acid residuals. Fig. 2 shows the docking pose and interactions of molecule 85 ​at the N3-binding site of COVID-19 Mpro (pdb: 6lu7).

Table 3.

Energies of the main interactions of N1, N10-dicoumaroyl spermidine (compound 85) with amino acid residuals of binding site of COVID-19 Mpro. (M ​= ​main chain; S ​= ​side chain).

H bonds
vdW interactions
Residual Energy Residual Energy
M-Ser 144 −3.50 M-Thr 25 −1.87
S-Ser 144 −2.50 S-Thr 25 −3.03
M-Cys 145 −3.50 S-His 163 −3.05
S-Cys 145 −3.85 S-His 41 −1.68
M-Phe 140 −3.50
S-Glu 166 −2.44
S-Asn 142 −2.57
M-Gly 143 −0.48

Fig. 2.

Fig. 2

Interactions of N1,N10-dicoumaroylspermidine (compound 85) with the residuals in binding site of COVID-19 Mpro (pdb: 6lu7): a) 3D presentation; b) 2D presentation. (Green ​= ​conventional hydrogen bond; light green ​= ​carbon hydrogen bond; purple ​= ​π- π stacked interactions). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Compound 85 forms interactions with residuals in catalytic dyad composed of Cys144 and His41. It forms several strong hydrogen bonds: oxygen atom from one amide group forms hydrogen bonds with Cys145 (2.69 ​Å) and Ser144 (3.17 ​Å); nitrogen atom from amine group forms hydrogen bonds with Phe140 (3.01 ​Å) and Glu166 (3.25 ​Å), while nitrogen atom from second amide group forms H-bond with Asn142 (3.23 ​Å). Phenolic hydroxyl group generates carbon hydrogen bond with Asn142 (3.59 ​Å). Phenol ring from one coumaric acid generates π- π stacked interactions with Tyr118 (5.66 ​Å). Fig. 3 presents the surface of COVID-19 Mpro coloured by hydrogen bond type in complex with compound 85. Figure shows how compound 85 is situated in the gap between domains I and II. Recently, the crystal structure of COVID-19 virus Mpro in complex with N3 elucidated specific interactions of N3with Mpro [55]. N3 creates hydrogen bond with His 163 ​at S1 subsite and makes van der Waals contacts with Pro 168 and the backbone of residues 190–191. The bulky benzyl group forms van der Waals interactions with Thr 24 and Thr 25, similar as compound 85. Also, N3 forms multiple hydrogen bonds with the main chain of the residues in the substrate-binding pocket helping to lock the inhibitor inside the substrate-binding pocket. As stated, N3 and compound 85 bind to Mpro's in a similar mode.

Fig. 3.

Fig. 3

Surface of COVID-19 Mpro (pdb: 6lu7) coloured by hydrogen bond type, with receptor donors coloured in green and receptor acceptors in cyan in complex with compound N1,N10-dicoumaroyl spermidine compound (85). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

An obvious advantage of using food compounds is that most of the food compounds are less toxic to human body therefore they could serve as excellent starting points for developing a drug for a disease.

3.1. Structural analysis of food complexes from molecular dynamics simulations

Firstly, we computed the root-mean-square deviations (RMSD) of backbone atoms of protein for all the complexes relative to their initial structures. The time evolution of the RMSD of three complexes is shown in Fig. 4 (A). It is evident that RMSD values for 3CL Mpro complexes with ligand1, ligand2, and ligand3 remain stable after 75 ns depicting the convergence of simulations. Overall, within the last 125 ns, all systems got converged.

Fig. 4.

Fig. 4

(A) Time evolution of root-mean-square deviations (RMSDs) of backbone atoms, (B) the root-mean-square fluctuations (RMSFs) of Cα atoms, (C) radius of gyration, Rg of Cα atoms, and (D) solvent accessible surface area (SASA) of Mpro of three complexes relative to their respective energy minimized structure.

The average values of RMSDs for three complexes are listed in Table 4 . The average values vary between 1.61 ​± ​0.02 ​Å and 2.92 ​± ​0.06 ​Å. The highest deviation was observed for the complex1 (2.92 ​± ​0.06 ​Å), while the lowest was obtained for complex2 (1.62 ​± ​0.02 ​Å). It suggests that complex2 and complex3 are more stable than complex1 in the last 125 ns simulations based on average RMSD deviations. Higher RMSDs of complex1 is mainly attributed to extended loop rearrangement (residue 185–200) and domain III (residue 200–306) fluctuations.

Table 4.

The average backbone RMSD, the radius of gyration (Rg), and solvent accessible surface area (SASA) for the best three complexes. The data are reported as average ​± ​standard error of the mean (SEM).

System RMSD (Å) Rg (Å) SASA (Å2)
Complex1 2.92 ​± ​0.06 21.86 ​± ​0.02 14498.94 ​± ​32.46
Complex2 1.61 ​± ​0.02 21.96 ​± ​0.02 14213.10 ​± ​56.30
Complex3 1.78 ​± ​0.03 21.98 ​± ​0.01 14067.56 ​± ​32.02

Besides, to get more insight into the extent to which the binding of food compounds affects the Mpro structural fluctuation and flexibility in a single amino acid level during the MD simulation, the root means square fluctuation (RMSF) was analyzed, see Fig. 4(B). From the RMSF plot, we observed that complex1 is more flexible in the domain III region. Mainly, domain III is involved in forming a homodimer to be a reason for higher fluctuations in food compound, and domain I and II involved in ligand binding. We observed that those residues involved in food compound binding interactions show lower fluctuation than non-binding residues from the domain I and domain II. Residues Thr25, Thr26, Thr45, Cys44, Ser46, His41 are shows low fluctuations, and Leu50, Pro52, Asn51, Asn53, Glu55 shows high fluctuations from the domain I. Similarly, Ser144, Cys145, His164, Ser144, Gln189, Thr190, Asn142, Pro168, Met165, Gln192, and Ala191 residues from domain II shows low fluctuations. This suggests that food compound binding pocket residues are less flexible. The lower degree of fluctuation gives us a better compactness and rigidity complex structure.

As we know that the radius of gyration (Rg) helps us to understand the compactness of receptor protein, keeping mind, we monitored the Rg of Mpro through the entire 200 ns simulation and the time evolution of Rg shown in Fig. 4(C). The average values of Rg of three complexes are listed in Table 4. As evident from Table 4, all three complexes show more or less similar compactness. It could sometimes significantly affect the protein structure after binding a new ligand and side by side the solvent-accessible surface area (SASA) of changes. We know that SASA is very important for non-polar solvation energy measurement, directly affecting the ligand binding. Therefore, we also explored the SASA for three complexes and plotted with respect to simulation time, shown in Fig. 4(D). The average value of SASA varies from 14067.56 ​± ​32.02 ​Å2 to 14498.94 ​± ​32.46 ​Å2. The highest being reported for complex1 and low for the complex3.

To further explain the conformational stability, we also measured structural variations, RMSD of protein in its ligand-binding pocket, including all amino acids that fall within a radius of 5 ​Å from the ligand, see in Fig. 5 (A). Complex1 binding site RMSD fluctuates around 1 ​Å up to 100 ns after that deviation is increased by two-fold and fluctuating at ~2.3 ​Å. In the case of complex2, initial 30 ns, we see some drifting in the RMSD values, and after that up to 150 ns binding pocket residues fluctuating around 1 ​Å. Finally, it reached an equilibrium stage at a slightly higher RMSD value, i.e., 1.8 ​Å in the last 50 ns. For complex3, we see the increasing pattern of RMSD value in the first 50 ns after that reached stable equilibrium and fluctuating around 2 ​Å up to 200 ns. Overall, it suggests that the binding of a food compound in the binding site of Mpro stabilized the pocket conformation.

Fig. 5.

Fig. 5

(A) Time evolution of root-mean-square deviations (RMSDs) of backbone atoms binding pocket, (B) 2D potential of mean force (PMF) of ligands molecules concerning their heavy atoms RMSD, (C) center of mass (CoM) distance between domain I and ligand and (D) CoM distance between domain II and ligand of Mpro of three complexes relative to their respective energy minimized structure.

Furthermore, to determine the dynamics of the food compound throughout the simulations, the potential of mean force (PMF) was plotted w.r.t to RMSD of the food compound and shown in Fig. 5 (B). Fig. 5(B) showed that the ligand1 in complex1 showed a single global minimum at ​~ ​1.7 ​Å and exhibiting a very narrow peak and room temperature accessible secondary minimum at ~2.1 ​Å, suggesting the stability of the inhibitor in the binding site of the complex1. Ligand2 in complex2 also showed a single global minimum at ~2.2 ​Å and exhibiting a very narrow peak. The other secondary minimum structure was obtained at ~1.7 ​Å, but the energy barrier between these adjacent structures was high and found to be ~1.5 ​kcal/mol. Complex3 PMF profile shows a broad peak at 4 ​Å, and the conformational sampling space is wider relative to the other two complexes. Overall, the PMF profile of ligand molecules suggests that the ligand2 in the binding site is more flexible, reflecting on the binding affinity.

Finally, we monitored the CoM distance of food compounds and two vital domains involved in ligand binding, domain I and domain II, shown in Fig. 5 (C, D). In both cases, complex1 and complex2 maintain a stable distance. Fig. 5(C) indicates that ligand2 is positively shifted toward domain I, and ligand1 is 5 ​Å farther away from the domain I relative to ligand2. Initially, ligand3 is much far away from the domain I, but within 50 ns–125 ns, distance decreases, and the entire last 75 ns, it is stable around 18 ​Å. Similarly, ligand1 is shuffled toward domain II, and ligand 2 is 5 ​Å farther away from domain II than ligand1. Ligand3 shows a very flexible distance from domain II compared to ligand1 and 2. This time evolution of distances gives an important message to understand food compound behavior inside the binding pocket of SARS-CoV-2 main protease, Mpro.

3.2. Binding free energy analysis

To elucidate the binding mechanism of three food compounds to the Mpro using MM-GBSA analysis, we have computed the total binding energy and its various components contributing to the binding free energy (ΔG bind). The MM-GBSA based binding affinity calculations were performed on the production simulation trajectories. The various components include van der Waals interactions (ΔE vdW), electrostatic interactions (ΔE elec), polar solvation free energy (ΔG pol), and non-polar solvation free energy (ΔG np), which are listed in Table 5 and shown in Fig. 6 . It is evident that in all cases, food compound-Mpro complexation is favored by the van der Waal interactions (ΔE vdW) and electrostatic interactions (ΔE ele). The effects of solvent around the Mpro can also be studied, and it depicts that non-polar solvation free energy (ΔG np) favors the complexation. In contrast, the polar solvation free energy (ΔG pol) disfavor the complex formation.

Table 5.

Energetic components of the binding free energy of Mpro and food complexes in kcal/mol. Data are represented as average ​± ​SEM.

COMPONENTS COMPLEX1 COMPLEX2 COMPLEX3
ΔEVDW −45.9 ​± ​0.1 −37.1 ​± ​0.1 −40.9 ​± ​0.1
ΔEELEC −48.7 ​± ​0.3 −22.6 ​± ​0.2 −18.6 ​± ​0.2
ΔGPOL 67.6 ​± ​0.2 38.7 ​± ​0.1 33.8 ​± ​0.1
ΔGNP −6.7 ​± ​0 −5.1 ​± ​0 −5.6 ​± ​0
aΔGSOLV 60.9 ​± ​0.2 33.6 ​± ​0.1 28.2 ​± ​0.1
bΔGPOL + ELEC 18.9 ​± ​0.4 16.1 ​± ​0.2 15.2 ​± ​0.2
cΔEINTERNAL −94.6 ​± ​0.3 −59.7 ​± ​0.2 −59.5 ​± ​0.2
ΔGBINDSIM −33.7 ​± ​0.4 −26.1 ​± ​0.2 −31.3 ​± ​0.2
a

ΔGsolv ​= ​ΔGnp ​+ ​ΔGpol,

b

ΔGpol + elec ​= ​ΔEelec ​+ ​ΔGpol,

c

ΔEinternal ​= ​ΔEvdW ​+ ​ΔEelec.

Fig. 6.

Fig. 6

Energy components (kcal/mol) for binding food compounds to Mpro protein. ΔEvdW, van der Waals interaction; ΔEele, electrostatic interaction in the gas phase; ΔGpol, polar solvation energy; ΔGpol, non-polar solvation energy, and ΔGbind, estimated binding affinity.

It is evident from Table 5, the predicted binding free energies (ΔG bind) are −33.7 ​± ​0.4 ​kcal/mol, −26.1 ​± ​0.2 ​kcal/mol, and −31.3 ​± ​0.2 ​kcal/mol for complex1, complex2, and complex3, respectively. It suggests that the food compound, ligand1 (7), and ligand3 (85) binds strongly with the Mpro in comparison to ligand2 (17). As shown in Table 5, that for all complexes, van der Waals (ΔE vdW) varies between −37.1 ​± ​0.1 ​kcal/mol and −45.9 ​± ​0.1 ​kcal/mol, while in electrostatic interactions, ΔE elec ranges from −18.6 ​± ​0.2 to −48.7 ​± ​0.3 ​kcal/mol. The van der Waal interactions favor the most in complex2 and complex3 compared to the electrostatic interactions but in complex1 electrostatic interaction is higher than van der Waals. Furthermore, for all cases, the electrostatic interaction components, ΔE elec, are over-compensated by the polar desolvation energy, ΔGpol, suggesting that the total polar (ΔGpol + elec) components are unfavorable to the food compound binding toward Mpro. It is evident from Table 5 that the energy of ΔE ele and ΔE vdW for the complex2 was less favorable than complex1 as found to be −22.6 ​± ​0.2 ​kcal/mol and −37.1 ​± ​0.1 ​kcal/mol, respectively. So, the affinity of the three food compounds increases in the following order: ligand2 (17) ​< ​ligand3 (85) ​< ​ligand1 (7). Our results revealed that ligand1 (7) binds most strongly to Mpro due to the higher value of total internal molecular mechanics energy; Δ E internal is more favorable to the binding than the other two food compounds.

To further explore the critical residues involved in the food compounds' binding mechanism to SARS-CoV-2 main protease, we computed the per-residue decomposition of free energy using the MM-GBSA [56] method. The approach of per-residue based contributions is useful to determine the binding mechanisms at a residual atomistic level. The different energy contributions from each residue's backbone and side-chain are shown in Fig. 7 and listed in Table 6 . Here all the reported interacting residues energy contribution is −1.0 ​kcal/mol or higher.

Fig. 7.

Fig. 7

Decomposition of the binding free energy into contributions from individual residues for Mpro complexed with food compound. (A) for complex1, (B) for complex2 and (C) for complex3.

Table 6.

Decomposition of binding free energy into contributions from individual residuesa.

Residue EvdW Eelec Gpol Gnp Gside_chain Gbackbone Gtotal
Complex1
Ser144 −0.7 −2.6 1.6 −0.1 −0.7 −1.1 −1.8
Gln189 −1.3 −2.1 2.0 −0.3 −1.0 −0.7 −1.7
Asn142 −1.9 −2.1 2.8 −0.3 −0.6 −0.9 −1.5
Pro168 −1.7 0.3 0.1 −0.1 −1.2 −0.2 −1.4
Cys145 −1.2 −0.2 0.2 −0.1 −0.7 −0.6 −1.3
Met165 −1.0 −0.2 0.1 −0.1 −0.6 −0.6 −1.2
Complex2
Thr25 −1.0 −2.8 0.7 −0.2 −3.1 −0.2 −3.3
Thr45 −1.5 −2.3 1.2 −0.1 −1.0 −1.7 −2.7
Met49 −1.9 0 0.4 −0.3 −1.7 −0.1 −1.8
His41 −2.4 −1.4 2.5 −0.4 −1.1 −0.6 −1.7
Ser46 −1.7 −0.3 1.0 −0.3 −0.6 −0.7 −1.3
Gln189 −1.5 −0.7 1.2 −0.2 −0.7 −0.5 −1.2
Cys44 −1.1 −1.1 1.3 −0.2 −0.5 −0.6 −1.1
Leu27 −0.9 −0.2 0.2 −0.1 −0.9 −0.1 −1.0
Complex3
Gln189 −2.1 −3.4 3.1 −0.4 −2.2 −0.6 −2.8
Gln192 −1.1 −2.1 1.6 −0.1 −1.4 −0.3 −1.7
Met165 −1.5 −0.3 0.5 −0.1 −1.3 −0.1 −1.4
Met49 −1.2 −0.1 0.2 −0.2 −1.1 −0.2 −1.3
Ala191 −1.2 −0.2 0.4 −0.2 −0.6 −0.6 −1.2
His41 −1.5 −0.4 1.0 −0.2 −0.8 −0.3 −1.1
Pro168 −0.8 −0.1 0.1 −0.2 −0.8 −0.2 −1.0
a

Energetic contributions from the van der Waals (EvdW) and electrostatic interactions (Eelec) as well as polar (Gpol) and non-polar solvation energy (Gnp) and the total contribution of given residue (Gtotal) for SARS-CoV-2 Mpro-food compound complexes are listed. Gside_chain and Gbackbone represent the side chain and backbone contributions. Only residues with | ΔG | ≥ 1.0 ​kcal/mol are shown. All values are given in kcal/mol.

It is evident from Table 6 that the number of highly favorable residues in the food compound binding is more or less the same. As shown in Fig. 7(A), we observed that residues involved in binding ligand1 (7) are Ser144, Gln189, Asn142, Pro168, Cys145, and Met165. All these residues are located in domain II and form intense contact with ligand1. In Fig. 6(B), we found that residues Thr25, Thr45, Met49, His41, Ser46, Gln189, Cys44, and Leu27 are the most energy contributing amino acids to the binding of ligand2 (17). Most of these residues are located in domain I and make close contact with ligand2. Similarly, Table 6 and Fig. 6(C) suggested that ligand3 (85) and Mpro high energy contribution residues are Gln189. Gln192, Met165, Met49, Ala191, His41, and Pro168. These residues are mainly from domain I and domain II region. It can further be observed from Table 6 that the highest contributing residue ser144 and Gln189 from domain II for the case of ligand 1 (7) and ligand 3 (85). Overall, the identification of hotspot residues from our observation can facilitate the design of a new generation and highly selective inhibitor against SARS-CoV-2 Mpro.

3.3. Hydrogen bonding and hydrophobic interactions analysis

We performed production trajectory-based hydrogen bonds analysis for three food compound complexes to complement the binding free energy analysis, and more 10% occupancy hydrogen bonds are reported in Table 7 . The time evolution of hydrogen bonds for three complexes are also shown in Fig. 8 . As suggested by Fig. 8, we observed that complex1 has a relatively more significant number of total numbers of hydrogen bonds than the other two complexes. Furthermore, complex3 hydrogen bond time spectra have high dynamics. In complex1, critical residues involved in the hydrogen bonding are Asn142, Glu166, Gln189, Ser144, and Ser46. We found two stable hydrogens with more than 20% occupancy between ligand1 (7) and Mpro (Asn142@OD1-Lig@N1 and Glu166@OE2-Lig@N3) see in Table 7.

Table 7.

Main hydrogen bond interactions formed by SARS-CoV-2 Mpro with food compounds and the corresponding average distance and percentage of occupancy determined using the trajectories of production simulations. Hydrogen bonds with more than 10% occupancy are reported.

Acceptor Donor Avg. Distancea (Å) Occupancyb (%)
Complex1
Asn142@OD1 Lig@N1 2.85 22.17
Glu166@OE2 Lig@N3 2.85 20.62
Gln189@O Lig@O6 2.72 18.61
Lig@O2 Ser144@N 2.88 15.83
Lig@O2 His163@NE2 2.86 14.84
Glu166@OE2 Lig@N1 2.82 13.64
Glu166@OE1 Lig@N1 2.83 13.58
Ser46@O Lig@O6 2.74 12.90
Glu166@OE1 Lig@N3 2.85 12.86
Complex2
Thr25@OG1 Lig@O12 2.73 68.60
Thr45@O Lig@O7 2.77 30.35
Thr24@OG1 Lig@O11 2.91 18.83
His41@O Lig@O7 2.77 16.33
Gln189@OE1 Lig@O2 2.77 15.24
Thr24@OG1 Lig@O12 2.96 13.65
Lig@O4 Asn142@ND2 2.91 11.25
Lig@O12 Thr24@OG1 2.80 10.21
Complex3
Gln192@O Lig@N3 2.85 17.45
Cys44@O Lig@N3 2.92 16.56
Lig@N2 Gln192@NE2 2.93 15.10
Lig@O2 Gln189@NE2 2.85 14.68
Cys44@O Lig@N2 2.89 12.41
Met165@HG3 Lig@N2 2.78 10.11
His41@O Lig@O1 2.79 10.03
a

The hydrogen bonds are determined by the acceptor … donor distance of ≤3.5 ​Å and acceptor … H-donor angle of ≥120°.

b

Occupancy (to evaluate the stability and strength of the hydrogen bonds) is defined as the percentage of simulation time that a specific hydrogen bond exists, the hydrogen bonds occurring less than 10% of simulations are not shown.

Fig. 8.

Fig. 8

Time evolution of the number of hydrogen bonds between three food compounds and SARS-CoV-2 Mpro with respect to their initial conformations.

In the case of complex2, both Thr25 and Thr45 formed a hydrogen bond with ligand2 (17) with an occupancy of 68.60% (Thr25@OG1-Lig@O12) and 30.35% (Thr45@O-Lig@O7), respectively. Thr24, His41, Gln189, and Asn142 also formed hydrogen bonds with ligand2 (17) during our simulations with an occupancy range from 10% to 18%. Finally, in complex3, the hydrogen bonds' residues are Gln192, Cys44, Gln189, Met165, and His41. Both Gln192 and Cys44 form two hydrogen bonds with ligand3 (85) with an occupancy range of 12.41%–17.45%. On the other hand, His41 and Met165 form hydrogen bonds with an occupancy of ~10%, Met165@HG3-Lig@N2, and His41@O-Lig@O1, respectively.

Finally, we supplemented the above results by analyzing the final production simulation conformation with LigPlot ​+ ​software for each complex. The interacting residues, both hydrophobic and hydrogen, are shown in Fig. 9 , and side by side, its corresponding position in the protein structure is also shown in the right panel. Hydrogen bonds are depicted in green dotted lines, and red semicircles and dotted lines are involved in hydrophobic interactions. For complex1, Fig. 9(A and B) displayed, 13 hydrophobic interactions with His41, His164, His163, Gln189, Met165, Leu167, Pro168, His172, Ser139, Phe140, Leu141, Asn142 and Cys145 (blue color residues in Fig. 9(B)). Moreover, we also found four stable hydrogen bonds in the final conformation, shown in green color in Fig. 9(B). This large number of hydrophobic and hydrogen bonds interactions account for the high stability and good binding affinity of ligand1 (7) to SARS-CoV-2 Mpro. Ligand2 (17) formed hydrophobic interactions with Ser46, Cys44, His41, Asp187, Cys145, Gln189, and Met49 and hydrogen bonds with Thr24, Thr25 and Thr45, (see in Figure (C, D)). Finally, Figure (E, F) shows that complex3 formed hydrophobic interactions with Thr45, Ser46, Met49, His41, Arg188, Ala191, Leu167, Met165, His164 and Glu166 and four hydrogen bonds with Gln189, Thr190, Gln192, and Cys44. Overall, ligand1(7) and ligand3 (85) have a higher binding affinity against Mpro compared to ligand2 (17) due to a larger number of hydrophobic and hydrogen bonds interactions.

Fig. 9.

Fig. 9

The Mpro-food compound interactions profile for (A) complex1, (C) complex2, and (E) complex3. The food compounds are shown in balls and sticks. Hydrogen bonds are depicted in green dotted lines, and red semicircles and dotted lines are involved in hydrophobic interactions. Each interacting residual position in the binding pocket is shown in the right panel for (B) complex1, (D) complex2, and (F) complex3. The blue color residues are involved in hydrophobic interactions, and green color residues are involved in hydrogen bond formations. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

4. Conclusion

In conclusion, for the first time, a food database has been used in unique way to identify hits for COVID-19. The present docking studies along with robust support from molecular dynamics simulations indicated that two derivatives of spermidine exhibited high potential for binding to the active site of COVID-19 Mpro. The key structural features for the inhibition of COVID-19 main protease of N1,N10-dicoumaroyl spermidine are: nitrogen atom from amine group and phenolic hydroxyl groups. Study has revealed that spermidines, as food constituents, are interesting target for the development of a drug or natural healing of COVID-19 disease.

Authorship contributions

Category 1.

Conception and design of study: V. H. Masand, V. Rastija

acquisition of data: V. H. Masand, V. Rastija

analysis and/or interpretation of data: V. H. Masand, V. Rastija, P. Kar, M. Fulbabu.

Category 2.

Drafting the manuscript: V. H. Masand, V. Rastija, P. Kar, M.E.A. Zaki.

Revising the manuscript critically for important intellectual content: M.E.A. Zaki.

Category 3.

Approval of the version of the manuscript to be published (the names of all authors must be

listed): V. H. Masand, V. Rastija, P. Kar, M.E.A. Zaki, M. Fulbabu.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors are thankful to the Deanship of Scientific Research at Imam Mohammad Ibn Saud Isslamic University, Riyadh, KSA, for its support of this research through the Research Grant No. 21-13-18-070. PK acknowledges the research support by the Department of Biotechnology, Govt. of India (grant number BT/RLF/Re-entry/40/2014, Ramalingaswami Re-entry Fellowship). MFS receives PhD fellowship from DST-INSPIRE, Govt. of India.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.chemolab.2021.104394.

Appendix A. Supplementary data

The following are the Supplementary data to this article:

Multimedia component 1
mmc1.xlsx (13.4KB, xlsx)
Multimedia component 2
mmc2.csv (2.9KB, csv)
Multimedia component 3
mmc3.docx (37.2KB, docx)

References

  • 1.Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368:409–412. doi: 10.1126/science.abb3405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y., Wang Q., Xu Y., Li M., Li X., Zheng M., Chen L., Li H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B. 2020;10:766–788. doi: 10.1016/j.apsb.2020.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Masand V.H., Rastija V., Patil M.K., Gandhi A., Chapolikar A. Extending the identification of structural features responsible for anti-SARS-CoV activity of peptide-type compounds using QSAR modelling. SAR QSAR Environ. Res. 2020;31:643–654. doi: 10.1080/1062936X.2020.1784271. [DOI] [PubMed] [Google Scholar]
  • 4.Masand V.H., Akasapu S., Gandhi A., Rastija V., Patil M.K. Structure features of peptide-type SARS-CoV main protease inhibitors: quantitative structure activity relationship study. Chemometr. Intell. Lab. Syst. 2020:206. doi: 10.1016/j.chemolab.2020.104172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Khan R.J., Jha R.K., Amera G.M., Jain M., Singh E., Pathak A., Singh R.P., Muthukumaran J., Singh A.K. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase. J. Biomol. Struct. Dyn. 2020:1–14. doi: 10.1080/07391102.2020.1753577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Chilamakuri R., Agarwal S. COVID-19: characteristics and therapeutics. Cells. 2021:10. doi: 10.3390/cells10020206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Mulholland A.J., Amaro R.E. COVID19 - computational chemists meet the moment. J. Chem. Inf. Model. 2020;60:5724–5726. doi: 10.1021/acs.jcim.0c01395. [DOI] [PubMed] [Google Scholar]
  • 8.Tripathi N., Tripathi N., Goshisht M.K. Molecular Diversity; 2021. COVID-19: Inflammatory Responses, Structure-Based Drug Design and Potential Therapeutics. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. The Lancet Respiratory Medicine. 2021:e20–e21. doi: 10.1016/S2213-2600(21)00005-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X., You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W., Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y. [DOI] [PubMed] [Google Scholar]
  • 11.Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S., Shum D., Kim S. vol. 64. 2020. (Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs, Antimicrobial Agents and Chemotherapy). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fu L., Ye F., Feng Y., Yu F., Wang Q., Wu Y., Zhao C., Sun H., Huang B., Niu P., Song H., Shi Y., Li X., Tan W., Qi J., Gao G.F. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 2020;11 doi: 10.1038/s41467-020-18233-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Chowdhury P. In silico investigation of phytoconstituents from Indian medicinal herb ‘Tinospora cordifolia (giloy)’ against SARS-CoV-2 (COVID-19) by molecular dynamics approach. J. Biomol. Struct. Dyn. 2020:1–18. doi: 10.1080/07391102.2020.1803968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhou Y., Hou Y., Shen J., Huang Y., Martin W., Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14. doi: 10.1038/s41421-020-0153-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wang F., Chen C., Tan W., Yang K., Yang H. Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design. Sci. Rep. 2016;6:22677. doi: 10.1038/srep22677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Childs Calder, miles, diet and immune function. Nutrients. 2019;11 doi: 10.3390/nu11081933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Teodoro A.J. Bioactive compounds of food: their role in the prevention and treatment of diseases. Oxidative.Med.Cell. Longevity. 2019;2019:1–4. doi: 10.1155/2019/3765986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hsu K.-C., Chen Y.-F., Lin S.-R., Yang J.-M. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinf. 2011;12:S33. doi: 10.1186/1471-2105-12-S1-S33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Case D.A., Ben-Shalom I.Y., Brozell S.R., Cerutti D.S., Cheatham I.T.E., Cruzeiro V.W.D., Darden T.A., Duke R.E., Ghoreishi D., Gilson M.K., Gohlke H., Goetz A.W., Greene D., Harris R., Homeyer N., Huang Y., Izadi S., Kovalenko A., Kurtzman T., Lee T.S., LeGrand S., Li P., Lin C., Liu J., Luchko T., Luo R., Mermelstein D.J., Merz K.M., Miao Y., Monard G., Nguyen C., Nguyen H., Omelyan I., Onufriev A., Pan F., Qi R., Roe D.R., Roitberg A., Sagui C., Schott-Verdugo S., Shen J., Simmerling C.L., Smith J., SalomonFerrer R., Swails J., Walker R.C., Wang J., Wei H., Wolf R.M., Wu X., Xiao L., Y D.M., Kollman a.P.A. University of California; San Francisco: 2018. AMBER 2018. [Google Scholar]
  • 20.Maier J.A., Martinez C., Kasavajhala K., Wickstrom L., Hauser K.E., Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theor. Comput. 2015;11:3696–3713. doi: 10.1021/acs.jctc.5b00255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. Development and testing of a general amber force field. J. Comput. Chem. 2004;25:1157–1174. doi: 10.1002/jcc.20035. [DOI] [PubMed] [Google Scholar]
  • 22.Olsson M.H., Søndergaard C.R., Rostkowski M., Jensen J.H. PROPKA3: consistent treatment of internal and surface residues in empirical p K a predictions. J. Chem. Theor. Comput. 2011;7:525–537. doi: 10.1021/ct100578z. [DOI] [PubMed] [Google Scholar]
  • 23.Jakalian A., Jack D.B., J C.I.J., Bayly o.c.c. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J. Comput. Chem. 2002;23:1623–1641. doi: 10.1002/jcc.10128. [DOI] [PubMed] [Google Scholar]
  • 24.Wang J., Wang W., Kollman P.A., Case D.A. Antechamber: an accessory software package for molecular mechanical calculations. J. Chem. Inf. Comput. Sci. 2001;222:U403. [Google Scholar]
  • 25.Price D.J., Brooks C.L., III A modified TIP3P water potential for simulation with Ewald summation. J. Chem. Phys. 2004;121:10096–10103. doi: 10.1063/1.1808117. [DOI] [PubMed] [Google Scholar]
  • 26.Salomon-Ferrer R., Case D.A., Walker R.C. An overview of the Amber biomolecular simulation package. Wiley Interdisciplinary Reviews: Computational Molecular Science. 2013;3:198–210. [Google Scholar]
  • 27.Kräutler V., Van Gunsteren W.F., Hünenberger P.H. A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J. Comput. Chem. 2001;22:501–508. [Google Scholar]
  • 28.Darden T., York D., Pedersen L. Particle mesh Ewald: an N⋅ log (N) method for Ewald sums in large systems. J. Chem. Phys. 1993;98:10089–10092. [Google Scholar]
  • 29.Loncharich R.J., Brooks B.R., Pastor R.W. Langevin dynamics of peptides: the frictional dependence of isomerization rates of N-acetylalanyl-N′-methylamide. Biopolymers: Original Research on Biomolecules. 1992;32:523–535. doi: 10.1002/bip.360320508. [DOI] [PubMed] [Google Scholar]
  • 30.Berendsen H.J., Postma J.v., van Gunsteren W.F., DiNola A., Haak J. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984;81:3684–3690. [Google Scholar]
  • 31.Jonniya N.A., Sk M.F., Kar P. Investigating phosphorylation-induced conformational changes in WNK1 kinase by molecular dynamics simulations. ACS Omega. 2019;4:17404–17416. doi: 10.1021/acsomega.9b02187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Singh S., Sk M.F., Sonawane A., Kar P., Sadhukhan S. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis. J. Biomol. Struct. Dyn. 2020:1–16. doi: 10.1080/07391102.2020.1796810. just-accepted. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sk M.F., Jonniya N.A., Kar P. Exploring the energetic basis of binding of currently used drugs against HIV-1 subtype CRF01_AE protease via molecular dynamics simulations. J. Biomol. Struct. Dyn. 2020:1–18. doi: 10.1080/07391102.2020.1794965. just accepted. [DOI] [PubMed] [Google Scholar]
  • 34.Sk M.F., Roy R., Jonniya N.A., Poddar S., Kar P. Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations. J. Biomol. Struct. Dyn. 2020:1–21. doi: 10.1080/07391102.2020.1768149. just accepted. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Sk M.F., Roy R., Kar P. Exploring the potency of currently used drugs against HIV-1 protease of subtype D variant by using multiscale simulations. J. Biomol. Struct. Dyn. 2020 doi: 10.1080/07391102.07392020.01724196. just-accepted. [DOI] [PubMed] [Google Scholar]
  • 36.Jonniya N.A., Sk M.F., Kar P. A comparative study of structural and conformational properties of WNK kinase isoforms bound to an inhibitor: insights from molecular dynamic simulations. J. Biomol. Struct. Dyn. 2020 doi: 10.1080/07391102.07392020.01827035. Just accepted. [DOI] [PubMed] [Google Scholar]
  • 37.Sk M.F., Jonniya N.A., Roy R., Poddar S., Kar P. Computational investigation of structural dynamics of SARS-CoV-2 methyltransferase-stimulatory factor heterodimer nsp16/nsp10 bound to the cofactor SAM. ChemRxiv. 2020 doi: 10.26434/chemrxiv.12608795.v1. [Preprint] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Roe D.R., Cheatham T.E., III PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theor. Comput. 2013;9:3084–3095. doi: 10.1021/ct400341p. [DOI] [PubMed] [Google Scholar]
  • 39.Barrett P., Hunter J., Miller J.T., Hsu J.-C., Greenfield P. Astronomical data analysis software and systems XIV; 2005. matplotlib--A Portable Python Plotting Package; p. 91. [Google Scholar]
  • 40.Kollman P.A., Massova I., Reyes C., Kuhn B., Huo S., Chong L., Lee M., Lee T., Duan Y., Wang W. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 2000;33:889–897. doi: 10.1021/ar000033j. [DOI] [PubMed] [Google Scholar]
  • 41.Wang J., Wang W., Kollman P.A., Case D.A. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph. Model. 2006;25:247–260. doi: 10.1016/j.jmgm.2005.12.005. [DOI] [PubMed] [Google Scholar]
  • 42.Bartels C., Karplus M. Multidimensional adaptive umbrella sampling: applications to main chain and side chain peptide conformations. J. Comput. Chem. 1997;18:1450–1462. [Google Scholar]
  • 43.Kar P., Knecht V. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase. J. Phys. Chem. B. 2012;116:6137–6149. doi: 10.1021/jp3022612. [DOI] [PubMed] [Google Scholar]
  • 44.Kar P., Knecht V. Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease. J. Phys. Chem. B. 2012;116:2605–2614. doi: 10.1021/jp211768n. [DOI] [PubMed] [Google Scholar]
  • 45.Kar P., Knecht V. Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir. J. Comput. Aided Mol. Des. 2012;26:215–232. doi: 10.1007/s10822-012-9550-5. [DOI] [PubMed] [Google Scholar]
  • 46.Kar P., Knecht V. Energetics of mutation-induced changes in potency of lersivirine against HIV-1 reverse transcriptase. J. Phys. Chem. B. 2012;116:6269–6278. doi: 10.1021/jp300818c. [DOI] [PubMed] [Google Scholar]
  • 47.Kar P., Lipowsky R., Knecht V. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease. J. Phys. Chem. B. 2013;117:5793–5805. doi: 10.1021/jp3085292. [DOI] [PubMed] [Google Scholar]
  • 48.Roy R., Ghosh B., Kar P. Investigating conformational dynamics of Lewis Y oligosaccharides and elucidating blood group dependency of cholera using molecular dynamics. ACS Omega. 2020;5:3932–3942. doi: 10.1021/acsomega.9b03398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Gohlke H., Case D.A. Converging free energy estimates: MM-PB (GB) SA studies on the protein–protein complex Ras–Raf. J. Comput. Chem. 2004;25:238–250. doi: 10.1002/jcc.10379. [DOI] [PubMed] [Google Scholar]
  • 50.Still W.C., Tempczyk A., Hawley R.C., Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990;112:6127–6129. [Google Scholar]
  • 51.Feig M., Onufriev A., Lee M.S., Im W., Case D.A., Brooks C.L., III Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. J. Comput. Chem. 2004;25:265–284. doi: 10.1002/jcc.10378. [DOI] [PubMed] [Google Scholar]
  • 52.Miller B.R., III, McGee T.D., Jr., Swails J.M., Homeyer N., Gohlke H., Roitberg A.E. MMPBSA. py: an efficient program for end-state free energy calculations. J. Chem. Theor. Comput. 2012;8:3314–3321. doi: 10.1021/ct300418h. [DOI] [PubMed] [Google Scholar]
  • 53.Onufriev A., Bashford D., Case D.A. Exploring protein native states and large-scale conformational changes with a modified generalized born model, Proteins: structure, Function. Bioinformatics. 2004;55:383–394. doi: 10.1002/prot.20033. [DOI] [PubMed] [Google Scholar]
  • 54.Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. Des. Sel. 1995;8:127–134. doi: 10.1093/protein/8.2.127. [DOI] [PubMed] [Google Scholar]
  • 55.Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020:1–5. doi: 10.1038/s41586-020-2223-y. [DOI] [PubMed] [Google Scholar]
  • 56.Genheden S., Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expet Opin. Drug Discov. 2015;10:449–461. doi: 10.1517/17460441.2015.1032936. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.xlsx (13.4KB, xlsx)
Multimedia component 2
mmc2.csv (2.9KB, csv)
Multimedia component 3
mmc3.docx (37.2KB, docx)

Articles from Chemometrics and Intelligent Laboratory Systems are provided here courtesy of Elsevier

RESOURCES